OP has been using alfatradiol and a mix of rosemary, peppermint, and jojoba oils for hair loss, with inconsistent dermapen sessions. They plan to add topical finasteride at 0.025% later.
The user experienced headaches and brain fog with a topical solution containing Dutasteride, Minoxidil, Tretinoin, Fluocinolone, Latanoprost, and Caffeine. They are considering switching to oral or topical Finasteride to see if it alleviates these side effects.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
Sulfur soap may help with hair thickening and reducing scalp inflammation, but it can cause dryness. Nizoral, containing ketoconazole, is noted for its potential to reduce seborrheic dermatitis but may also cause scalp dryness and hair loss.
Minoxidil is causing severe scalp irritation, including itchiness and dryness, for the user. Alternatives suggested include anti-fungal treatments, propylene-glycol-free formulations, and possibly oral minoxidil.
The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
Switching from minoxidil foam to topical solution and considering adding caffeine, melatonin, or cetirizine. Currently using 2.5mg oral minoxidil and 1mg oral finasteride, planning to ask for 0.5mg oral dutasteride and 5mg oral minoxidil.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.
Topical aldactone is discussed for its effects on men's hair and muscles. The conversation explores its potential benefits and side effects compared to other treatments like Minoxidil, finasteride, and RU58841.
The user is seeking recommendations for scalp-friendly minoxidil and RU58841 products available in the UK, as previous products caused scalp inflammation. They mention issues with RUDirect and MinoxidilMax products.
A user experienced heart palpitations and breathing issues while using oral finasteride and minoxidil for hair loss and plans to switch to generic finasteride and topical minoxidil. They also use Nizoral shampoo and are considering a moisturizing shampoo due to dryness and itchiness.
Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
User experienced scalp irritation from Kirkland 5% liquid minoxidil, likely due to propylene glycol. They are seeking non-PG liquid alternatives that are affordable.
Minoxidil may inhibit collagen synthesis at high concentrations, with anecdotal reports of skin aging but limited research. Dermatologists and other specialists show little interest in studying minoxidil's side effects.
KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.
Stopping saw palmetto and rosemary oil led to significant hair loss for a long-term finasteride user. Resuming saw palmetto caused side effects, and there is debate about its effectiveness and the potential impact of oxycodone on hair loss.
The conversation is about finding a reliable source for oral minoxidil in Turkey, preferably in original packaging, and concerns about the safety and effectiveness of local products. The user is seeking recommendations for trustworthy suppliers and is wary of counterfeit products and scams.
Catalase is discussed as a potential treatment for delaying or reversing grey hair, but no reliable medicine currently exists. Other mentioned treatments include Imatinib, senolytics like Quercetin and Fisetin, He Shou Wu, Argan oil, and reishi mushroom extract, though their effectiveness varies.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
The user is taking 2.5mg of oral Minoxidil and using Rosemary and Peppermint oil for hair regrowth, with no side effects reported. They are considering increasing the dosage to 5mg after three months and have been advised to include a dermaroller in their routine.
The conversation discusses using minoxidil 5% with azelaic acid for hair loss treatment. Users share tips on sourcing and mixing azelaic acid with minoxidil.
Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.